Arrowstreet Capital, Limited Partnership Kodiak Sciences Inc. Transaction History

Arrowstreet Capital, Limited Partnership

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$4.3 - $9.48 $298,054 - $657,106	69,315 Added 275.97%	94,432 $652,000
Q1 2023 May 15, 2023	BUY	$4.81 - $8.88 $60,682 - $112,030	12,616 Added 100.92%	25,117 $156,000
Q4 2022 Feb 14, 2023	BUY	$6.52 - $8.05 $81,506 - $100,633	12,501 New	12,501 $90,000
Q3 2020 Nov 12, 2020	SELL	$45.05 - $59.27 $468,519 - $616,408	-10,400 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$42.74 - $66.25 $444,496 - $689,000	10,400 New	10,400 $563,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.